Connect to other sites within the UBM Medica Network
Carbonyl Compounds in Breath Could Help Diagnose Lung Cancer
Six carbonyl compounds in exhaled breath can effectively discriminate between lung cancer patients and healthy patients, says a new study.
Carfilzomib Gets Expanded FDA Approval for Multiple Myeloma
The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.
Younger CRC Patients Often Have Hereditary Syndromes
Patients diagnosed with colorectal cancer at younger ages are more likely to have an underlying hereditary syndrome than older patients, according to a new study.
Gemcitabine With EBRT Shows Promise in Soft-Tissue Sarcoma
In a phase I study, gemcitabine given concurrently with fixed-dose EBRT showed promising results following surgery in patients with high-risk soft-tissue sarcoma.
Two Inexpensive Drugs Can Reduce Breast Cancer Deaths
A pair of studies suggest that aromatase inhibitors and bisphosphonates can each improve survival for postmenopausal women with early breast cancer.
RT Offers Little to No Survival Boost in Early Breast Cancer
Two trials reported marginal or no improvement in survival with nodal irradiation in early breast cancer patients, though reductions were seen in recurrence.
Tivantinib With Erlotinib Fails to Improve OS in NSCLC
Adding tivantinib to erlotinib improved progression-free survival but not overall survival in patients with previously treated non-small-cell lung cancer.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
By clicking Accept, you agree to become a member of the UBM Medica Community.